111 Inc (YI) - Net Assets
Based on the latest financial reports, 111 Inc (YI) has net assets worth $218.81 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.48 Billion) and total liabilities ($2.26 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check YI financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $218.81 Million |
| % of Total Assets | 8.81% |
| Annual Growth Rate | -5.03% |
| 5-Year Change | -71.39% |
| 10-Year Change | N/A |
| Growth Volatility | 106.61 |
111 Inc - Net Assets Trend (2016–2024)
This chart illustrates how 111 Inc's net assets have evolved over time, based on quarterly financial data. Also explore 111 Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for 111 Inc (2016–2024)
The table below shows the annual net assets of 111 Inc from 2016 to 2024. For live valuation and market cap data, see 111 Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $380.76 Million | +37.91% |
| 2023-12-31 | $276.10 Million | -57.41% |
| 2022-12-31 | $648.24 Million | -23.62% |
| 2021-12-31 | $848.71 Million | -36.22% |
| 2020-12-31 | $1.33 Billion | +71.94% |
| 2019-12-31 | $773.92 Million | -36.76% |
| 2018-12-31 | $1.22 Billion | +283.84% |
| 2017-12-31 | $318.82 Million | -44.60% |
| 2016-12-31 | $575.52 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 111 Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 312893400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $58.00K | % |
| Other Comprehensive Income | $74.36 Million | % |
| Other Components | $3.17 Billion | % |
| Total Equity | $-642.64 Million | 100.00% |
111 Inc Competitors by Market Cap
The table below lists competitors of 111 Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Haiwan International Development Co Ltd
TWO:3252
|
$30.44 Million |
|
Reviva Pharmaceuticals Holdings Inc.
NASDAQ:RVPH
|
$30.45 Million |
|
Allwin Telecommunication Co Ltd
SHE:002231
|
$30.45 Million |
|
Unite Group PLC
LSE:UTG
|
$30.45 Million |
|
Trajectory Alpha Acquisition Corp
NYSE:TCOA
|
$30.40 Million |
|
Yong Shun Chemical Co Ltd
TWO:4711
|
$30.39 Million |
|
Atec T& Co. Ltd
KQ:224110
|
$30.39 Million |
|
Heartbeam Inc
NASDAQ:BEAT
|
$30.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 111 Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -583,451,000 to -642,644,000, a change of -59,193,000.
- Net loss of 64,743,000 reduced equity.
- New share issuances of 14,000 increased equity.
- Other comprehensive income increased equity by 1,843,000.
- Other factors increased equity by 3,693,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-64.74 Million | -10.07% |
| Share Issuances | $14.00K | +0.0% |
| Other Comprehensive Income | $1.84 Million | +0.29% |
| Other Changes | $3.69 Million | +0.57% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares 111 Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $6.92 | $6.00 | x |
| 2017-12-31 | $3.93 | $6.00 | x |
| 2018-12-31 | $24.62 | $6.00 | x |
| 2019-12-31 | $94.90 | $6.00 | x |
| 2020-12-31 | $43.38 | $6.00 | x |
| 2021-12-31 | $-20.90 | $6.00 | x |
| 2022-12-31 | $-49.76 | $6.00 | x |
| 2023-12-31 | $-69.21 | $6.00 | x |
| 2024-12-31 | $-74.58 | $6.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 111 Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.45%
- • Asset Turnover: 5.17x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-40.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -63.26% | -41.50% | 0.93x | 1.64x | $-420.01 Million |
| 2017 | -78.32% | -25.91% | 1.26x | 2.41x | $-280.32 Million |
| 2018 | -31.05% | -21.28% | 1.15x | 1.26x | $-502.52 Million |
| 2019 | -64.61% | -12.70% | 2.45x | 2.07x | $-579.49 Million |
| 2020 | -127.74% | -5.57% | 2.71x | 8.47x | $-492.27 Million |
| 2021 | 0.00% | -5.39% | 3.95x | 0.00x | $-652.48 Million |
| 2022 | 0.00% | -3.08% | 3.89x | 0.00x | $-375.42 Million |
| 2023 | 0.00% | -2.63% | 4.84x | 0.00x | $-334.35 Million |
| 2024 | 0.00% | -0.45% | 5.17x | 0.00x | $-478.60K |
Industry Comparison
This section compares 111 Inc's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $1,073,291,921
- Average return on equity (ROE) among peers: -23.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 111 Inc (YI) | $218.81 Million | -63.26% | 10.34x | $30.40 Million |
| Accendra Health Inc (ACH) | $565.23 Million | -64.17% | 7.24x | $147.73 Million |
| Akso Health Group ADR (AHG) | $17.27 Million | -201.64% | 0.83x | $807.33 Million |
| Cardinal Health Inc (CAH) | $54.00 Million | 12.22% | 2.53x | $45.94 Billion |
| Cencora Inc. (COR) | $75.30 Million | 67.07% | 19.61x | $59.14 Billion |
| Cosmos Health Inc. (COSM) | $-53.68K | 0.00% | 0.00x | $10.83 Million |
| EDAP TMS SA (EDAP) | $19.41 Million | -151.12% | 3.07x | $126.31 Million |
| Empro Group Inc. Ordinary shares (EMPG) | $1.41 Million | 82.70% | 1.73x | $143.05 Million |
| Henry Schein Inc (HSIC) | $3.66 Billion | 0.00% | 1.14x | $8.70 Billion |
| McKesson Corporation (MCK) | $6.27 Billion | 15.35% | 2.82x | $99.71 Billion |
| Owens & Minor Inc (OMI) | $70.80 Million | 9.18% | 1.18x | $185.63 Million |
About 111 Inc
111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2C and B2B. The company offers supply chain integration services that help pharmaceutical companies manage products through online and offline channels; product promotion, customer analytics, patient education,… Read more